Navigation Links
Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study
Date:9/6/2012

THURSDAY, Sept. 6 (HealthDay News) -- A new review finds that rheumatoid arthritis medications known as biologics don't raise the risk of cancer, contrary to what some previous research has suggested.

Rheumatoid arthritis affects an estimated 1 percent of the general population, with women three times more likely to have it. Different from age-related osteoarthritis, rheumatoid arthritis is debilitating autoimmune disorder that causes inflammation of the lining of the joints.

Biologics work by targeting specific parts of the immune system involved in the inflammation process.

Previous studies have raised questions about whether the drugs might boost the risk of cancer. The new study appears in the Sept. 5 issue of the Journal of the American Medical Association.

The researchers, led by a researcher at the University of Texas M.D. Anderson Cancer Center, looked at 63 randomized controlled trials of the drugs that featured follow-up periods of at least 24 weeks. In total, the studies analyzed nearly 29,500 patients.

The biologic medications are abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), rituximab (Rituxan), and tocilizumab (Actemra).

The analysis didn't find any extra risk of cancer compared to other drugs for rheumatic arthritis or a placebo.

The drugs are commonly used to treat rheumatoid arthritis, said Dr. Nadera Sweiss, an associate professor of medicine at the University of Illinois at Chicago College of Medicine who was not involved with the study.

"Biologic therapy revolutionized the treatment of [rheumatoid arthritis]," she said, and explained that these drugs are "introduced earlier in the disease course to control inflammatory activity early on and decrease the risk of disability."

Fear of cancer, however, has been a major issue for patients, she said, especially in those who may need to be on the medications for life.

As for the new analysis, she praised it but said it's limited because it examines the effect of the drugs up to 24 weeks. "There is still a concern about long-term safety," she said.

More information:

For more about rheumatoid arthritis, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Nadera Sweiss, M.D., associate professor, medicine, University of Illinois at Chicago College of Medicine; Sept. 5, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Antidepressants May Be Safe for Parkinsons Patients
2. Newer Second-Line Diabetes Drug May Outperform Older Meds
3. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
4. Newer technology to control blood sugar works better than conventional methods
5. Newer hip reconstruction technique provides good outcomes for athletes
6. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
7. Older Antipsychotics May Work as Well as Newer Ones: Review
8. Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
9. Newer Drug-Releasing Stent Cuts Chances of Cardiac Events: Study
10. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
11. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
(Date:11/30/2016)... Wisconsin (PRWEB) , ... November 30, 2016 , ... ... in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of the ... year on the list, having ranked from 2008-2016. In addition, Standard Process was ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... and mental health treatment has announced the opening of a new residential mental ... for girls with mental health issues such as severe anxiety, depression, bi-polar disorder, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... stylish design wanted by today’s consumers at an affordable price, is now available ... the new watch is “a game changer” when it comes to the smartwatch. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2016  The Addiction Treatment Advisory Group (ATAG), ... Care Pharmacy (AMCP), has released detailed findings on ... opioid addiction crisis, including through improved access to ... ATAG,s newly released paper, "The Role of Managed ... many issues around gaps and barriers to addiction ...
(Date:12/2/2016)... 2, 2016 Boston Scientific Corporation (NYSE: ... acquire certain manufacturing assets and capabilities of the Neovasc, ... biological tissue business, as well as a 15% equity ... in cash. The Neovasc advanced biological tissue business makes ... Scientific Lotus™ Valve System. * Upon completion of ...
Breaking Medicine Technology: